GLP-1 Weight-Loss
Projector
See the average weight-loss trajectory reported in the pivotal trials for your starting weight and medication — the trend, not a promise. Individual results vary widely.
Your details
Projected average weight at plateau (~68–72 wks)
Expected trajectory
How this works
Methodology reviewed July 2026This projector shows the average total-body-weight trajectory reported in the pivotal weight-loss trials — STEP 1 for semaglutide, SURMOUNT-1 for tirzepatide, and SCALE for liraglutide — for your starting weight and chosen dose. Each medication/dose carries the trial-average percent weight change at full titration, applied to your weight and spread over ~68–72 weeks using an exponential approach-to-plateau curve (about 90% of total loss reached by week 52). It draws the trial-average trajectory achieved with lifestyle support under clinical supervision — not a personal promise. It is a way to set expectations, not a target.
Total loss = current weight × (trial-average % change at full dose)
Weight at week t = current weight − total loss × (1 − e^(−K·t)), K = 0.045
Week reaching X% of bodyweight lost = −ln(1 − X/totalPct) / K
BMI = weight(kg) / height(m)²
Trial-average endpoints used: tirzepatide 5/10/15 mg = −15.0 / −19.5 / −20.9%;
semaglutide 1.0/2.4 mg = −10.6 / −14.9%; liraglutide 3.0 mg = −8.0%
Current weight · Units (lb/kg) · Height (optional · for BMI) · Medication and dose
Projected average weight at plateau · Total weight lost and percent · BMI now and at plateau · Week reaching 5% and 10% loss · Trajectory by week
- You reach and tolerate the full selected dose with lifestyle support, as in the trials.
- Loss follows a smooth exponential approach to a plateau around week 68–72.
- Trial-average endpoints are representative of the modeled trajectory.
- These are trial averages — individual results vary widely, from far more to far less loss.
- Real weight loss is not smooth; plateaus, water shifts, and adherence dips alter the path.
- The curve does not account for your diet, training, comorbidities, or dose held below full titration.
- Use this to set expectations, not targets — and only under clinical supervision.
- A trial-average trajectory is not a prediction of your outcome; do not treat a shortfall as failure.
References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM (2021)
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM (2022)
- Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM (2015)
This calculator is for educational purposes only and is not medical advice, diagnosis, or treatment. Results are estimates based on published formulas and population averages — your individual values may differ. Nothing here is calculated on a server: everything runs in your browser and no data is stored or sent anywhere. Always consult a qualified clinician before making health, medication, or training decisions.